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Zusammenfassung
Ziel: Evaluierung der prognostischen Bedeutung der Lokalisation und
desAusmaßesderregionärenLymphknotenmetastasierungbeimrese-
zierten,nicht-kleinzelligenLungencarcinoms(NSCLC),sowiedesEinflus-
ses der Therapiemodalitäten auf das Langzeitüberleben.
Patienten und Methode: Im Rahmen der explorativen Analyse wurden
die Patienten nach Lokalisation und Zeitpunkt der Diagnose der
Lymphknotenmetastasierung gruppiert: Gruppe I, pN2-Erkrankung in
der aorto-pulmonalen Region (N=14); Gruppe II, pN2-Erkrankung in
andererLokalisation(N=30);GruppeIII,cN2-ErkrankungmitAnsprechen
auf die Induktionstherapie (ypN0; N=21); Gruppe IV, cN2-Erkrankung
ohne Ansprechen auf die Induktionstherapie (ypN1-2; N=27); Gruppe
V, pN1-Erkrankung (N=66).
Resultate: Im Zeitraum 1999–2005, wurden 158 Patienten (Altersme-
dian:64Jahre)mitnodal-positivemNSCLCentwedereinerneoadjuvan-
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Research Article OPEN ACCESSten Chemo-Radiotherapie und chirurgischen Resektion oder der chirur-
gischenResektionplusadjuvanterTherapie(Chemotherapie,Radiothe-
rapie, oder beides) unterzogen. Die chirurgische Mortalität und höher-
gradigeMorbiditätbetrugen2%respektive15%.DieÜberlebensanalyse
ergab 5-Jahresüberlebensraten von 19% für die Gruppe I, 12% für die
Gruppe II, 66% für die Gruppe III, 15% für die Gruppe IV und 29% für
die Gruppe V (P<0,05). Bei der multivariaten Analyse korrelierten Zeit-
punktderDiagnoseundAusmaßderLymphknotenmetastasierungsowie
das therapeutische Konzept signifikant mit der Prognose der Erkran-
kung.
Schlussfolgerung: Die Prognose der Patienten mit nodal-positivem
NSCLCwirdnichtvonderanatomischenLagederbefallenenLymphkno-
tenstationen beeinflusst, sondern von dem Ausmaß der regionären
Lymphknotenmetastasierung und den Therapiemodalitäten. Multimo-
dale Konzepte unter Einschluss der Chemotherapie und Chirurgie kön-
nen das Langzeitüberleben dieser Patientenpopulation verlängern.
Schlüsselwörter: Chemotherapie, Chirurgie, Induktionstherapie,
Lungencarcinom, Radiotherapie
Introduction
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer-related mortality in the world. Currently, only
few cases are diagnosed at an early stage of tumour: at
thetimeofdetectiononly15%ofpatientshaveadisease
localized to their lung, in 22% of cases the cancer has
spread to regional lymph nodes, and in 55% distant
metastases are already present, while 8% of cancers re-
main unstaged [1].
Patients with NSCLC and metastases in the ipsilateral
nodes of the mediastinum (N2) represent a population
with markedly prognostic heterogeneity, ranging from
cases with multiple confluent or extranodal invasion,
evident at the clinical/radiological staging, to cases with
multilevel nodal disease detected only at mediastino-
scopy, up to patients with limited nodal spread and nor-
mal appearance on CT scan, revealed accidentally in the
final pathology report [2], [3], [4]. Similar heterogeneity
has been advocated for N1-disease, although recent re-
ports do not confirm this finding [5], [6]. The presence of
clinically evident, bulky nodal disease is accompanied in
most cases – regardless of the intensity of treatment –
bypoorsurvival.Ontheotherhand,metastasisinasingle
nodal station with closed anatomical relationship to the
lobe of origin of the primary tumour has been correlated
with a more favourable outcome, comparable with that
of N1-disease [7].
In recent years, the results of many studies have led to
the evolution of standard management of nodal positive
NSCLC, as chemotherapy either in the neoadjuvant or in
theadjuvantsettinghasbecomeamainstayoftreatment
[8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18],
[19], [20]. Nevertheless, there is a still ongoing debate
whetherselectedpatientswithnode-positiveNSCLCwith
“more favourable” prognosis should be primarily treated
with surgery alone. Particularly, patients with nodal dis-
easerestrictedtoasinglestationproximaltotheprimary
tumourareoftenconsideredsurgicalcandidates–asfor
instance the situation of a tumour in the left upper lobe
with lymph node metastasis in the aorto-pulmonary (A-P)
region. However, the benefit of surgery alone may be
limited, with 5-year survival rates in the order of 20 to
25% [2], [21], [22]. The aim of our exploratory data ana-
lysis was to investigate the prognostic significance of
anatomicallocationandextentoflymphnodemetastasis
inresectedNSCLC,e.g.bycomparingisolatedN2-disease
in the A-P region with other sites of nodal metastasis, as
wellastoidentifytheoptimaltherapyapproachfornode-
positive NSCLC.
Materials and methods
Patient population
In a retrospective analysis, we reviewed a series of 158
patients with non-small cell lung cancer (NSCLC) found
to be node-positive either at mediastinoscopy or at the
timeofsurgicalresection.Allpatientsweretreatedatthe
Department of Thoracic Surgery of the Niels-Stensen-
Kliniken, Ostercappeln, Germany between 1999 and
2005. Median age was 63 years (range 33–84), the
majority of patients was male (80%) and showed a WHO
performancestatusof0–1(91%).Abouttwo-thirdsofthe
patients (70%) had an acceptable pulmonary reserve,
the forced expiratory volume at 1 second (FEV1) measur-
ing 70% or more of the predicted value.
Patients were staged by chest X-ray examination, com-
puted tomography scan of chest and upper abdomen,
magnetic resonance imaging of the brain, abdominal ul-
trasound, bone scintigraphy, and bronchoscopy. As
positron emission tomography (PET) was not available at
thetimeofthestudy,cervicalmediastinoscopywasdone
in most cases (77%) for nodal staging; reasons for not
including mediastinoscopy in the remaining cases were:
peripheral T1-tumor, and mediastinal lymph nodes not
enlarged (less diameter <1 cm) on imaging studies. Pa-
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primarysurgicalresection,whereasthosewithN2-disease
underwent induction chemotherapy and concurrent
chemo-radiotherapy, and were subsequently operated
on.
Induction therapy in patients with
N2-nodes at mediastinoscopy
As one of the participating centres of the Münster study,
we adopted a modified induction protocol as described
by Thomas and coworkers [9].
In patients with N2-nodes at mediastinoscopy, induction
therapyconsistedof2coursesofplatin-basedchemother-
apy, followed by concurrent chemo-radiation based on
twice-daily hyperfractionated accelerated radiotherapy
andsingle-agentchemotherapy(cisplatin)asradiosensit-
izer. Eligible patients were scheduled for two courses of
chemotherapywithcisplatin70mg/m
2intravenously(IV)
on days 1 and 7 (or 8) and etoposide 150 mg/m
2 IV on
days 3, 4, and 5. Since 2001, cisplatin was administered
at 100 mg/m
2 IV and etoposide was replaced by gemcit-
abine 1000 mg/m
2 IV on day 1 and 8. The cycles were
repeated every 22 days. As scheduled, concurrent
chemoradiotherapywasstartedatweek7withtwice-daily
hyperfractionated accelerated radiotherapy (1.5 Gy per
fraction>6hoursapart,5daysaweek,uptoatotaldose
of 45 Gy over a period of 3 weeks) and single-agent
chemotherapy (cisplatin 8 mg/m
2 IV daily) during the
whole course of irradiation.
Two weeks after completion of radiotherapy, complete
restaging procedures except of mediastinoscopy were
performedandfollowedbydefinitivesurgery,4to6weeks
after the end of radiation. Mediastinal restaging was
based essentially on computed tomography criteria: en-
larged mediastinal lymph nodes with the minimum dia-
meter greater than 2 cm have been considered as har-
bouring persistent metastatic disease, and in that case
patients were excluded from surgical resection. In all
other cases surgical exploration was planned.
Surgical procedures
Surgical procedures included lobectomies, sleeve lobec-
tomies or pneumonectomies as indicated. In all cases a
systematic lymphadenectomy of the interlobar, hilar, and
ipsilateral mediastinal lymph node stations was per-
formed, and labeled according to the New Regional
Lymph Node Classification for Lung Cancer Staging [23].
These N-stage descriptors have not been substantially
changedintheSeventhEditionoftheTNMClassification
for Lung Cancer [6], [24].
Adjuvant therapy
As most patients were treated in an era before adjuvant
chemotherapy became standard of care for stage IIIA-
NSCLC, the majority of those treated by primary surgery
received adjuvant radiotherapy. After induction chemo-
radiotherapy and surgery, adjuvant treatment with two
additional courses of chemotherapy was planned if the
tumour was classified as responder. Non-responders did
not receive any adjuvant treatment and underwent
second-line chemotherapy as disease progression was
assessed.
In case of incomplete resection of the primary tumour, a
radiotherapy-boost, after-loading therapy, or both were
delivered according to the site of residual tumour.
Grouping according to the lymph node
status
For the purpose of this study, patients were grouped ac-
cording to the location and the timing of diagnosis of
nodal disease as follows:
• group I, N2-disease in the A-P region at thoracotomy
(level 5 and 6);
• group II, N2-disease at any other level at thoracotomy
(level 2, 3, 4, 7, 8, 9);
• group III, N2-disease at mediastinoscopy (level 2, 4,
7) with complete response to induction treatment;
• group IV, N2-disease at mediastinoscopy (level 2, 4,
7) with partial or no response to induction treatment;
• group V, N1-disease in the hilar or interlobar region at
thoracotomy (level 10, 11). We decided to include tu-
mours with hilar N1-metastases in the exploratory
analysis, because these have been advocated as
having a prognosis comparable to single-level N2-dis-
ease [5].
The grouping system is graphically represented in
Figure 1. The clinical characteristics of the groups are
indicated in Table 1.
Response evaluation
Before and after treatment, patients were staged using
the 1997 International Union Against Cancer (UICC) cri-
teria [25], as to the time of analysis the Seventh Edition
of TNM Classification of Malignant Tumours was not yet
definitely approved [26]. Responses to treatment were
assessed using standard EORTC/NCIC criteria [27]. Sur-
gical resection was defined as complete if the following
criteria were met: free resection margins proved micro-
scopically; systematic nodal dissection or lobe-specific
systematic nodal dissection; no extracapsular nodal ex-
tension of the tumour; and the highest mediastinal node
removed to be negative. Lymph node mapping at medi-
astinoscopy or surgery was accomplished according the
classification of Mountain and Dresler [23].
Follow-up and statistical methods
All patients were monitored every 3 months for the first
2yearsfromtheendoftreatmentandfromthenonevery
6 months. Survival was measured from the first day of
chemotherapy (mediastinoscopy positive N2-groups) or
from the day of surgery (other groups) until death, loss
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Marra et al.: Prognostic factors of resected node-positive lung ...Table 1: Comparison between groups of patients with node-positive NSCLC: clinical data. Group I, N2-disease in the AP-region;
groupII,N2-diseaseatanyotherlevel;groupIII,N2-diseaseatmediastinoscopywithcompleteresponsetoinductiontreatment;
group IV, N2-disease at mediastinoscopy with partial or no response to induction treatment; group V, N1-disease in the hilar or
interlobar region.
Figure 1: Patient grouping according to the site and the timing of diagnosis of nodal disease
to follow-up, or the time of evaluation for this report.
Statisticalgroupcomparisonwasaccomplishedtoexplore
homogeneity bias: differences between categorical and
continuous variables were comparatively analyzed using
Pearson’s χ
2-test and Student’s t-test, respectively. Sur-
vivalcurveswereestimatedbythemethodofKaplanand
Meier; differences in the curves between groups of pa-
tientswereevaluatedusingalog-ranktest[28].Multivari-
ate analysis was based on the Cox proportional hazard
model[29].AllindicatedPvaluesaretwo-tailed.Analysis
was carried out using a software package (Statistical
Program for the Social Sciences, release 10.0.7; SPSS
Inc., Chicago, IL).
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groupII,N2-diseaseatanyotherlevel;groupIII,N2-diseaseatmediastinoscopywithcompleteresponsetoinductiontreatment;
group IV, N2-disease at mediastinoscopy with partial or no response to induction treatment; group V, N1-disease in the hilar or
interlobar region.
Results
Results of treatment
In the groups of patients undergoing multimodality ther-
apy (III and IV), grade 3–4 toxicity was observed in 19%
of cases. Due to preoperative patient selection by a
multidisciplinary panel of experts, surgical resection of
thetumourwaspossiblein157(99%)ofpatients;inonly
onecasethetumourwastechnicallyinoperableatthora-
cotomy.Lobectomywasthemostfrequent(71%)surgical
procedure; sleeve-lobectomy was performed in a higher
numberofcasesascomparedwithpneumonectomy(19%
vs. 9%). Surgical mortality and major morbidity were 2%
and 15%, respectively, and there was no significant dif-
ference between groups. Resection was incomplete in
11 (7%) patients. As a result of induction therapy, some
cases showed complete pathologic response of the
primary tumour in the multimodal groups (24% in group
III, and 7% in group IV, respectively). A complete or near
complete clearance of lymph node metastases was ob-
servedin86%and14%ofcasesofgroupIII,respectively.
According to the results of the pathological examination,
adjuvant radiotherapy was delivered to 54% of patients
in the surgical groups, and chemotherapy with or without
radiotherapy to 12%; 44% of patients did not undergo
postoperative treatment. In the multimodality therapy
groups, 42% of patients received adjuvant therapy (21%
radiotherapy and 21% chemotherapy with or without ra-
diotherapy,respectively).Adetailedcomparisonbetween
the groups according to the treatment is presented in
Table 2.
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Among the 158 patients, 98 (62%) suffered a relapse of
their tumour: this was loco-regional in 15 (9%), at distant
site in 64 (41%), combined loco-regional and distant in
13 (8%), and as a second lung primary in the remaining
6 (4%). Figure 2 illustrates the percentage distribution of
the first site of tumour relapse according to the modality
of nodal involvement. Loco-regional recurrence rate
among the groups was relatively homogeneous, ranging
from 13% to 29%. On the other hand, we observed
broaderdifferencesintheincidenceofsystemicrelapses:
in group V was 38%, in group I, II and III 50%, 53% and
52%, respectively, whereas in group IV rose to 70%.
Nevertheless, at statistical analysis the differences con-
cerning first site of failure, frequency and type of local
recurrenceandmetastaseswerenotstatisticallysignific-
ant.
Figure 2: Percentage distribution of the first site of tumour
relapse in node-positive NSCLC patients according to the
modality of nodal involvement. Group I, N2-disease in the
AP-region; group II, N2-disease at other level; group III,
N2-disease at mediastinoscopy with complete response to
induction treatment; group IV, N2-disease at mediastinoscopy
with partial or no response to induction treatment; group V,
N1-disease in the hilar or interlobar region.
Survival analysis
Overall, patients were followed up for a median period of
41 months (range 4–104 months). Only three (2%) pa-
tients were lost to follow-up after 4, 6, and 12 months,
respectively.
Themediansurvivaltimeforthewholepatientpopulation
was 27 months (95%-CI: 22-32), with a 3- and 5-year
survival rate of 38% and 27%, respectively. On survival
analysis according to our grouping system, responders
afterinductiontherapy(groupIII)hadthebestprognosis:
theirmediansurvivaltimeof84months(95%-CI:59-109)
wassignificantlybetterthanthatofgroupII(P=.001)and
groupIV(P=.004),whereasthedifferencestogroupIand
groupVdidnotreachthestatisticalsignificance(P=.060
and P=.094, respectively) (Figure 3).
Onunivariateanalysis,followingclinicalandpathological
features had no significant impact on survival: WHO per-
formance status (0–1 vs. 2), gender, site of the primary
tumour, lobe of origin, cT classification, histology, type of
surgery, surgical complications, R-status.
Major prognostic factors were the type of lymph node in-
volvement according to the cited grouping system
(P=.0029)(Figure3),pTclassification(P=.0429),number
of involved nodal levels (P<.0001) (Figure 4), and type
of therapy added to surgery (P=.0284) (Figure 5).
We analyzed separately patients undergoing either local
therapymodalitiesonly(surgerywithorwithoutradiother-
apy) or therapy protocols including chemotherapy (in
neoadjuvant setting, adjuvant setting, or both): survival
was better in the chemotherapy group, although the dif-
ference was not statistically significant (P=.22). Thus, in
order to identify subsets of patients who benefit from
multimodal therapy including chemotherapy, the
chemotherapy group was split in a subgroup receiving
induction chemoradiotherapy with complete response to
therapy (CxRtS-R), a subgroup receiving induction
chemoradiotherapywithoutcompleteresponsetotherapy
(CxRtS-NR), and a subgroup receiving adjuvant chemo-
therapy(Cxadjuv),respectively,andthesewerecompared
with the local therapy group (local Tx). Survival curves
showedtheCxRtS-Rgrouptobeassociatedwiththebest
outcome, and the CxRtS-NR group with the worst; there-
after, patients undergoing adjuvant chemotherapy did
better as compared with those receiving local therapy
only. Survival differences were statistically significant
(P=.0075; Figure 6).
On multivariate analysis, type and extent of lymph node
involvement as well as the type of therapy added to sur-
geryweresignificantlylinkedtoprognosisofpatientswith
node-positive NSCLC (P=.002, P=.004 and P=.007, re-
spectively).
Discussion
In the current study, we analyzed whether anatomical
location and extent of lymph node metastases influence
theprognosisofNSCLC.Also,wecomparedmanagement
strategies of resected node positive NSCLC patients ac-
cording to type and location of nodal involvement.
Despite of the retrospective, and thus potentially biased
nature of the study, and the limited sample size, some
interesting findings have emerged from data analysis to
address the primary issues.
Anatomical location of nodal disease
The first finding was that there were no significant differ-
ences in survival between N2-disease in the AP-region
and N2-disease at other level, even when stratifying
groups by extent of nodal involvement, i.e. single vs.
multilevel. An additional observation was that in the A-P
regionsubgroupsurvivalwasnotinfluencedbymultilevel
nodal metastases, while such constellation in other me-
diastinal locations clearly worsened the prognosis.
The relationship between anatomical location of primary
tumour and lymph node metastases and prognosis of
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Marra et al.: Prognostic factors of resected node-positive lung ...Figure3:Overallsurvivalofpatientsaccordingtothemodalityofnodalinvolvement.GroupI,N2-diseaseintheAP-region;group
II, N2-disease at other level; group III, N2-disease at mediastinoscopy with complete response to induction treatment; group
IV,N2-diseaseatmediastinoscopywithpartialornoresponsetoinductiontreatment;groupV,N1-diseaseinthehilarorinterlobar
region.5-yr-SR, 5-year survival rate.
Figure4:Overallsurvivalofpatientsaccordingtotheamountoflymphnodeinvolvement.N2single,singlelevelnodalmetastasis;
N2 multi, multilevel nodal metastasis.
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Marra et al.: Prognostic factors of resected node-positive lung ...Figure5:Overallsurvivalofpatientsaccordingtothetypeofadjuvanttherapy.Cx(Rt),chemotherapywithorwithoutradiotherapy;
Rt, radiotherapy.
Figure 6: Overall survival of patients according to the treatment modality. CxRtS-R, chemo-radiotherapy and surgery with
complete nodal response to therapy; CxRtS-NR, chemo-radiotherapy and surgery without complete nodal response to therapy;
Cx adjuv, adjuvant chemotherapy; Tx, local treatment modality (surgery with or without radiotherapy)
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leagues analyzed the results of the Eastern Cooperative
Oncology Group (ECOG) 3590 trial by site of primary tu-
mourandpatternoflymphnodemetastases[21].Partic-
ularly,theycomparedsurvivalofpatientswithsingle-level
mediastinal involvement with that of patients with N1-
diseaseoriginatinginthesamelobe:mediansurvivalwas
35 months for the former group and 65 months for the
latter one, respectively (P=.02). This is in contrast to our
finding of comparable prognosis for patients with either
N1- or single-level N2-disease (median survival: 30 vs.
33 months, respectively; P=ns). This can be explained by
the different therapeutic approaches for patients with
N1-disease between the studies: in fact, all patients in
the ECOG 3590 trial received either adjuvant chemora-
diotherapy (52%) or adjuvant radiotherapy (48%), while
in our series adjuvant therapy was administered to only
41% of N1-patients.
Interestingly, Keller et al. observed that in patients with
tumour originating in the left upper lobe survival of the
subgroup with single-level N2 metastases was compar-
able to that of the subgroup with N1 disease (median
survival, 51 vs. 49 months; P=ns) [21]. This is in accord-
ance with our finding of similar outcomes between the
two subgroups (median survival of 32 months for single-
level A-P region N2 patients vs. 30 months for N1 pa-
tients; P=ns).
Extent of nodal involvement
Another remarkable result of our study was the effect of
continuousworseningofprognosiswithincreasingextent
of nodal involvement (Figure 2), although the difference
betweenN1-diseaseandsingle-levelN2-diseasewasnot
statisticallysignificant.Thepresenceofmultilevelinvolve-
ment carried disappointingly low survival rates, with a
median survival time of 10 months. This confirms previ-
ous reports of the literature: Sagawa et al. [22], in fact,
reported that 41% of 94 patients with a single involved
mediastinallevelwere5-yearsurvivors,andthedifference
between the ratio for these patients and that in the pa-
tients with 2 or more involved levels (13%) was highly
significant(P=0.001)[22].Inananalysisofpatientswith
resected N2-disease NSCLC, Andre et al. reported that
the5-yearsurvivalratesforpatientswithsingle-leveland
multilevel N2 disease detected during surgery were 34%
and 11%, respectively (P=.0001). In that series, the sur-
vival of patients with multilevel disease was close to that
of patients with preoperatively detected N2 and stage
IIIBdisease.Ontheotherhand,theprognosisofpatients
with single-level disease was similar to that of cases with
stage IIB reported in the literature [30]. Similar findings
on the prognostic power of extent of nodal involvement
have been also outlined by Keller and coll. [21], and Ri-
quet and coll. [31].
Therapeutic approach to node-positive
disease
On the multivariate analysis of our series, the third major
determinant of survival, beyond time of diagnosis and
extentofnodalinvolvement,wastheadditionofsystemic
therapy to surgery.
Patients receiving postoperative chemotherapy, alone or
in combination with radiotherapy, did significantly better
as compared with patients treated by surgery alone, but
there were no relevant differences with the group under-
going adjuvant radiotherapy. In order to investigate the
relative contribution of systemic therapy in improving
survival, we compared patients treated by approaches
including chemotherapy (pre- or postoperatively) with
those treated by local procedures, i.e. surgery with or
without radiotherapy, exclusively. Survival analysis
showed a moderate advantage for the chemotherapy
group, but this was not statistically significant (5-year
survival rates, 36% vs. 27%; P=ns). By splitting the
chemotherapy group into subpopulations according to
the timing of systemic therapy, we could identify categor-
iesofpatientswithmarkedlydifferentprognosis.Patients
receiving induction chemotherapy with clearance of
nodal metastases (“responders”) had a very favourable
long-term outcome, whereas those without mediastinal
clearance(“nonresponders”)didworst;patientsreceiving
chemotherapyinanadjuvantsettinghadanintermediate
prognosis, though superior to the local therapy group, as
shown in Figure 5.
Wewouldliketofocusonpatientsgroupswitha“clinical”
N2-disease – thus with preoperatively detected nodal
disease: In previous series, surgery alone did not lead to
a survival advantage in these patients; even in cases of
“complete”resection,long-termsurvivorsweretheexcep-
tionratherthantherule[30].Thereafter,severalrandom-
ized trials of the early 90’s showed a clear benefit of
multimodalityprotocolsincludinginductionchemotherapy
priortosurgeryforclinicalN2-disease[32],[33].However,
such improvement in the prognosis was not reserved for
allpatients,asthepersistenceofnodaldiseaseatsurgery
was associated with poor outcome despite complete re-
section [34], [35], [36], [37]. This justified our decision
tosplitthepatientsgroupwithclinicalN2-diseaseunder-
goinginductionchemo-radiotherapyandsurgeryintotwo
subgroups according to the nodal response. Responders
showedthebestlong-termoutcome(mediansurvival:84
months; 5-yr survival rate: 66%), comparable with stage
I disease; this result reflects an effective control of either
locoregionaldiseaseandoccultmetastases.Ontheother
side, non-responders (median survival: 17 months; 5-yr
survival rate: 15%) fared worse even than the group of
patients treated by surgery alone or in combination with
radiotherapy. As most of them (74%) died of recurrent
disease, it is recognisable that chemotherapy failed to
eradicate either nodal metastases in mediastinum and
distant micrometastases, which later appeared as a re-
currence. Thus, the presence of persistent lymph node
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as a reliable marker of non-controlled disease. The con-
tribution of surgical resection to improve survival in such
cases is questionable.
The group of patients receiving adjuvant chemotherapy
showedanintermediateoutcomebetweenthetwoformer
groups. It is likely that this group includes potential “re-
sponders”andcaseswithchemo-resistantoccultdisease.
Unfortunately, the adjuvant setting lacks a response
marker such as the nodal status to discriminate respon-
ders from non-responders.
ForpatientswithclinicalN2-diseaseundergoinginduction
therapy, the crucial point is to detect persistent disease
before surgery, in order to discriminate “true” resectable
cases from those at high risk of occult metastases.
However, the issue of accurate restaging of mediastinal
nodes is still a matter of debate. Computed tomography
(CT) scan has shown limited value in restaging of lung
cancer,particularlyinthedetectionofmediastinallymph
node metastases [38]. Positron emission tomography
with18F-2-fluoro-2-deoxy-D-glucose(FDG-PET)hasgained
an accepted value for the response evaluation after in-
duction treatment, particularly when integrated with CT
scan [39], [40]. Recently, the minimally invasive tech-
niques of transoesophageal endoscopic ultrasound-
guided fine needle aspiration (EUS-FNA) and endoscopic
transbronchialultrasonographywithfineneedleaspiration
biopsy(EBUS-FNAB)havebecomeclinicallyavailableand
may reach high accuracy in the primary staging of lung
cancer, under the condition that the suspicious lymph
nodes on CT or PET scan are targeted. A systematic ex-
ploration of the mediastinum is usually not included.
Thereafter, its value in the restaging setting is not ad-
equately defined and requires further investigation [41],
[42], [43]. Finally, remediastinoscopy is generally con-
sidered by many thoracic surgeons as a hazardous and
inaccurateprocedure,especiallyafterinductionprotocols
including radiotherapy. However, some reports on repeat
surgicalexplorationofmediastinumaspartofmultimod-
ality protocols suggested remediastinoscopy to be a safe
and accurate tool [38], [44], [45].
Whereas the overall survival benefit of platinum-based
chemotherapy, either in the adjuvant or in the neoad-
juvant setting, over surgery alone has been accepted on
thebasisofrandomizedtrialsandmeta-analyses[8],[9],
[10], [11], [12], [13], [14], [15], [16], [17], [18], [19],
[20],[46],[47],[48],theoptimaltimingofchemotherapy
in multimodality protocols remains still under investiga-
tion. Induction therapy has claimed some potential ad-
vantages: treatment of occult metastases at the earliest
possibletime,downstagingofprimarytumoursthatcould
result in a higher rate of complete resection, higher
compliance to treatment, and an in-vivo assessment of
tumourchemosensitivitywithasolidend-pointrepresent-
ed by pathologic response. Theoretical disadvantages
include a delay in potentially curative surgery (e.g. in the
non-responders population), and increased surgical
morbidityandmortality,especiallywhenpneumonectomy
needs to be performed. Nevertheless, current evidence
on neoadjuvant chemotherapy shows an effect that is
comparable to the one described in meta-analyses on
adjuvantchemotherapy[49],[50].Forthisreason,several
comparative trials randomizing between adjuvant and
neoadjuvantchemotherapyareaddressingthisquestion.
In conclusion, survival of patients with N2-NSCLC does
not depend on the anatomical location of nodal disease,
but is strongly correlated to the extent of nodal meta-
stases or rather the number of involved node levels. The
outcome of patients with node-positive NSCLC seems to
be significantly influenced by the treatment modality, as
the addition of chemotherapy to surgical resection, with
or without radiotherapy, may improve long-term survival
rates. Our series confirms previous findings, that the
clearance of mediastinal lymph node metastases after
inductiontreatmentinassociationwithcompletesurgical
resectionoffersthebestprognosisamongthesepatients;
therefore, all staging efforts should be applied to identify
those patients, for whom resection is associated with
prolonged survival. If this is possible at the present time,
one of the major goals for the next future will be to en-
hancetherateofmediastinaldownstaging,e.g.bymeans
of targeted induction treatment. As a targeted drug ther-
apy is currently feasible in about 20% of adenocarcino-
mas, further investigations should address this issue in
at least a subset of patients with node-positive lung can-
cer.
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